title: Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer.
abstract: The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has evolved rapidly with the recent approval of a number of treatments and agents, including docetaxel, sipuleucel T, abiraterone, cabazitaxel, and enzalutamide. Enzalutamide (previously MDV-3100) is a novel oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. The randomized phase III AFFIRM study demonstrated significant improvements in a number of efficacy endpoints, including the primary endpoint of overall survival and secondary endpoints of progression-free survival, and time to prostate-specific antigen progression in patients with progressive mCRPC who had received prior treatment with docetaxel. Enzalutamide was well tolerated and there were comparable incidences of grade 3 or greater adverse events reported for the enzalutamide and placebo control arms in AFFIRM. Unlike some other treatments for mCRPC, enzalutamide does not require administration with steroids. The ongoing randomized phase III PREVAIL trial will investigate the efficacy and safety of enzalutamide in chemotherapy-naïve patients with mCRPC. Additional trials are investigating the use of enzalutamide in a number of disease settings.
authors.affiliation: Professor and Chair, Division of Urology, University of Montreal Hospital Center and CRCHUM, CHUM, 1560 Sherbrooke East, Montreal Quebec H2L 4M1, Canada.
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
keywords: AFFIRM trial; PREVAIL trial; enzalutamide; metastatic castrate resistant prostate cancer
references.citation: Lancet. 2010 Apr 24;375(9724):1437-46
references.pmid: 20398925
references.citation: Ann Oncol. 2014 Feb;25(2):429-34
references.pmid: 24478320
references.citation: Urol Oncol. 2009 Jan-Feb;27(1):36-41
references.pmid: 19111796
references.citation: Adv Exp Med Biol. 2008;617:223-34
references.pmid: 18497046
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Lancet Oncol. 2012 Oct;13(10):983-92
references.pmid: 22995653
references.citation: Science. 2009 May 8;324(5928):787-90
references.pmid: 19359544
references.citation: J Clin Oncol. 2008 Jan 10;26(2):242-5
references.pmid: 18182665
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Br J Cancer. 2004 Jun 14;90(12):2317-25
references.pmid: 15150570
references.citation: Ann Oncol. 2013 Jan;24(1):31-8
references.pmid: 22831986
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553